Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia.
Lea TschaidseNicole ReischWiebeke ArltAude Brac de la PerriereAngelica Linden HirschbergAnders JuulAshwini MallappaDeborah P MerkeJohn D C Newell-PriceColin G PerryAlessandro PreteD Aled ReesNike StikkelbroeckPhilippe A TouraineHelen CoopeJohn PorterRichard John M RossMarcus QuinklerPublished in: European journal of endocrinology (2023)
6 months of MR-HC therapy decreased PRA and increased sodium levels indicating a greater agonist action of the 9α-fluorocortisol dose, which may be due to the decreased levels of the MC-receptor antagonist 17OHP.